Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OSUR 
OraSure Technologies Inc (OSUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: OSUR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 204.78M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 4 | Beta 0.91 | 52 Weeks Range 2.08 - 4.22 | Updated Date 02/26/2026 |
52 Weeks Range 2.08 - 4.22 | Updated Date 02/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-25 | When - | Estimate -0.19 | Actual -0.19 |
Profitability
Profit Margin -47.92% | Operating Margin (TTM) -58.02% |
Management Effectiveness
Return on Assets (TTM) -8.8% | Return on Equity (TTM) -15.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8465769 | Price to Sales(TTM) 1.63 |
Enterprise Value 8465769 | Price to Sales(TTM) 1.63 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 2.22 | Shares Outstanding 71733530 | Shares Floating 63667095 |
Shares Outstanding 71733530 | Shares Floating 63667095 | ||
Percent Insiders 5.96 | Percent Institutions 86.51 |
Upturn AI SWOT
OraSure Technologies Inc
Company Overview
History and Background
OraSure Technologies, Inc. was founded in 1988 and is a leader in point-of-care diagnostic and monitoring solutions. The company has evolved significantly, with key milestones including the development of oral fluid diagnostic devices, expansion into infectious disease testing, and strategic acquisitions to broaden its product portfolio and market reach.
Core Business Areas
- Diagnostics: Designs, manufactures, and markets tests and devices for the detection of infectious diseases, such as HIV, Hepatitis C, and Zika. This segment also includes tests for drugs of abuse and alcohol.
- Molecular Solutions: Provides advanced molecular diagnostic products and services, including DNA/RNA collection devices and sample preparation technologies for research and clinical applications.
Leadership and Structure
OraSure Technologies, Inc. is led by a management team comprising a CEO, CFO, and various VPs overseeing operations, R&D, sales, and marketing. The company operates through its distinct business segments.
Top Products and Market Share
Key Offerings
- OraQuicku00ae ADVANCEu00ae Rapid HIV-1/2 Antibody Test: A leading rapid point-of-care test for HIV, widely used in clinical settings and public health initiatives. Competitors include Abbott Laboratories (Alere) and Bio-Rad Laboratories. Market share data is proprietary, but it holds a significant position in the rapid HIV testing market.
- IntelliCupu00ae: A device designed for the collection and stabilization of oral fluid samples for various diagnostic tests, including HIV and Hepatitis C. Competitors include other sample collection device manufacturers. This product is critical for the company's oral fluid testing strategy.
- OASISu00ae Molecular Collection Device: A device for collecting and stabilizing DNA/RNA samples for molecular diagnostics. Competitors include Norgen Biotek Corp. and Qiagen. This product is key to their Molecular Solutions segment.
Market Dynamics
Industry Overview
The point-of-care diagnostics market is growing rapidly, driven by the increasing demand for faster and more accessible diagnostic solutions, particularly for infectious diseases and chronic condition management. The molecular diagnostics sector is also experiencing significant growth due to advancements in genomic technologies.
Positioning
OraSure Technologies is well-positioned in the point-of-care diagnostics market, particularly with its established OraQuicku00ae brand. Its strength lies in its oral fluid collection technology and its focus on infectious disease testing. The company leverages its established distribution channels and partnerships to reach various healthcare settings.
Total Addressable Market (TAM)
The global point-of-care diagnostics market is projected to reach tens of billions of dollars. OraSure Technologies is a significant player within specific niches of this market, such as rapid HIV testing and molecular sample collection. Their positioning is strong in these segments, but they face competition across broader diagnostic areas.
Upturn SWOT Analysis
Strengths
- Established brand recognition with OraQuicku00ae
- Patented oral fluid collection technology
- Strong presence in infectious disease diagnostics
- Diversified product portfolio
Weaknesses
- Reliance on a few key products
- Competition from larger diagnostic companies
- Potential for regulatory hurdles
- Historically inconsistent revenue growth
Opportunities
- Expansion into new infectious disease markets
- Growth in molecular diagnostics and personalized medicine
- Strategic partnerships and acquisitions
- Increased global demand for point-of-care testing
Threats
- Intensifying competition
- Changes in healthcare reimbursement policies
- Emergence of new diagnostic technologies
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Bio-Rad Laboratories, Inc. (BIO)
- Qiagen N.V. (QGEN)
- QuidelOrtho Corporation (QDEL)
Competitive Landscape
OraSure competes in a highly competitive landscape with larger, more diversified players. Its advantage lies in its specialized oral fluid technology and established position in specific infectious disease tests. However, it faces challenges in matching the scale, R&D budgets, and market reach of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced periods of growth, particularly driven by its HIV testing products. However, profitability and consistent revenue growth have been challenges.
Future Projections: Analyst estimates for future growth should be consulted. Potential growth drivers include the expansion of its molecular diagnostics business and the adoption of its new testing platforms. Recent strategic initiatives aim to bolster future growth.
Recent Initiatives: OraSure has been focused on expanding its molecular diagnostics offerings and potentially exploring new therapeutic areas. Strategic partnerships and product development are key initiatives.
Summary
OraSure Technologies, Inc. holds a notable position in point-of-care diagnostics, particularly with its HIV tests, but faces profitability challenges and intense competition. Its proprietary oral fluid technology and expansion into molecular diagnostics offer growth potential. The company needs to focus on consistent revenue growth and improving its bottom line to solidify its market standing.
Similar Stocks
Sources and Disclaimers
Data Sources:
- OraSure Technologies Investor Relations
- Financial news outlets (e.g., Bloomberg, Reuters)
- Market research reports (general industry data)
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy is based on publicly available information and may not be exhaustive. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OraSure Technologies Inc
Exchange NASDAQ | Headquaters Bethlehem, PA, United States | ||
IPO Launch date 1986-11-12 | President, CEO & Director Ms. Carrie Eglinton Manner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 501 | Website https://www.orasure.com |
Full time employees 501 | Website https://www.orasure.com | ||
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic and specimen collection devices and products in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, the company offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.